10-Q: Harmony Biosciences Reports Q3 2024 Results: Revenue Growth and Pipeline Expansion

Harmony Biosciences reported a 16.1% increase in net product revenue for the third quarter of 2024, alongside significant advancements in their clinical pipeline.

Summary

• Harmony Biosciences reported a net product revenue of $186.0 million for the third quarter of 2024, a 16.1% increase compared to the same period in 2023.
• The company's gross profit for the quarter was $143.3 million, up from $128.0 million in the prior year.
• Operating expenses totaled $81.6 million, with research and development expenses increasing significantly to $25.4 million.
• Net income for the quarter was $46.1 million, compared to $38.5 million in the third quarter of 2023.
• For the nine months ended September 30, 2024, net product revenue reached $513.5 million, a 24.1% increase year-over-year.
• The company's cash, cash equivalents, and investments totaled $504.7 million as of September 30, 2024.
• Harmony is advancing multiple clinical programs, including those for idiopathic hypersomnia (IH), Prader-Willi Syndrome (PWS), and myotonic dystrophy type 1 (DM1).
• The company is also developing new formulations of pitolisant, including Pitolisant GR and Pitolisant HD.
• Harmony completed the acquisition of Zynerba Pharmaceuticals in October 2023 and Epygenix Therapeutics in April 2024, expanding its pipeline with ZYN002 and EPX100, respectively.
• The company is facing patent litigation related to generic versions of WAKIX.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong revenue growth, pipeline expansion, and strategic acquisitions. However, the increased operating expenses and patent litigation introduce some uncertainty, preventing a perfect score.

Positives

• The company experienced a significant increase in net product revenue, indicating strong market demand for WAKIX.
• Harmony is actively expanding its pipeline through acquisitions and in-licensing agreements.
• The company is making progress in developing new formulations of pitolisant, which could extend patent protection and provide additional therapeutic options.
• The company has a strong cash position, which will support ongoing operations and future growth initiatives.
• The company has achieved significant formulary access for WAKIX, ensuring broad patient access.
• The company has a growing number of unique healthcare professional prescribers of WAKIX.

Negatives

• The company's operating expenses increased significantly, particularly in research and development.
• The company is facing patent litigation related to generic versions of WAKIX, which could impact future revenue.
• The company's cost of product sales increased as a percentage of net revenue due to higher royalty tiers.
• The company's primary endpoint in the INTUNE study for idiopathic hypersomnia did not meet statistical significance.

Risks

• The company's future success depends on the successful development and commercialization of its product candidates.
• The company faces significant competition from other pharmaceutical and biotechnology companies.
• The company's ability to obtain regulatory approvals for its product candidates is uncertain.
• The company's financial performance could be negatively impacted by the outcome of ongoing patent litigation.
• The company's reliance on a single supplier for the active pharmaceutical ingredient (API) for WAKIX poses a supply chain risk.
• The company's future revenue may be impacted by changes in rebates and co-pay assistance.

Future Outlook

The company plans to submit a supplemental NDA (sNDA) for idiopathic hypersomnia (IH) in the fourth quarter of 2024. They also plan to initiate a pivotal bioequivalence study and dosing optimization study for Pitolisant GR in the first quarter of 2025 and Phase 3 registrational studies for Pitolisant HD in the second half of 2025. The company anticipates topline data from the ZYN002 Phase 3 study in mid-2025 and plans to initiate a Phase 3 registrational study for ZYN002 in 22q deletion syndrome in 2025. They also plan to file an IND for BP1.15205 in mid-2025 and begin first-in-human studies in the second half of 2025. The company plans to initiate a Phase 3 registrational clinical trial in patients with LGS in the fourth quarter of 2024 and a juvenile toxicology study for HBS-102 in the fourth quarter of 2024.

Management Comments

• We believe that pitolisants ability to regulate histamine gives it the potential to provide therapeutic benefit in other rare neurological diseases that are mediated through H 3 receptors and histamine signaling.
• We are targeting assets that will allow us to further leverage the expertise and infrastructure that we have successfully built at Harmony so we can optimize the benefit of internal synergies.
• We believe the total addressable market for ZYN002 among patients with FXS is approximately 25,000 people based on an estimated current FXS prevalence of up to 87,000 cases and up to 40,000 diagnosed FXS cases.
• We believe the total addressable market for EPX100 among patients with DS is approximately 5,000 people based on an estimated current DS prevalence of approximately 8,600 cases and approximately 7,000 diagnosed DS cases.
• We believe the total addressable market for EPX100 among patients with LGS is approximately 35,000 people based on an estimated current LGS prevalence of approximately 48,000 cases and 44,000 diagnosed LGS cases.

Industry Context

This announcement reflects the ongoing trend of pharmaceutical companies focusing on rare neurological disorders with high unmet medical needs. The company's strategy of acquiring and developing multiple assets aligns with the industry's push for pipeline diversification and leveraging existing expertise. The patent litigation highlights the competitive landscape and the challenges of maintaining market exclusivity for innovative therapies.

Comparison to Industry Standards

• Harmony's revenue growth of 16.1% in Q3 2024 is strong compared to the average growth rate of established pharmaceutical companies, but is not unusual for a company with a relatively new product in a niche market.
• The increase in R&D spending is consistent with the industry trend of investing heavily in pipeline development, particularly in the rare disease space. Companies like BioMarin Pharmaceutical and Sarepta Therapeutics also invest heavily in R&D for rare diseases.
• The acquisition of Zynerba and Epygenix is similar to strategies employed by other companies like Alexion Pharmaceuticals (now part of AstraZeneca) and Vertex Pharmaceuticals, which have grown through strategic acquisitions of assets in their therapeutic areas.
• The patent litigation is a common challenge for pharmaceutical companies, with many facing generic competition after their exclusivity periods expire. Companies like AbbVie and Amgen have faced similar challenges with their blockbuster drugs.
• Harmony's focus on histamine signaling is a unique approach compared to other companies in the sleep disorder space, which often target different neurotransmitter systems. This could provide a competitive advantage if their approach proves successful.

Legal Proceedings

• The company is involved in patent litigation related to generic versions of WAKIX.
• The company and its licensor, Bioprojet, filed complaints for patent infringement against multiple companies in response to their filing of ANDAs with the FDA.

Related Party Transactions

• The company has a right-of-use agreement with Paragon Biosciences, LLC, for office space in Chicago, Illinois.

Stakeholder Impact

• Shareholders may benefit from the company's revenue growth and pipeline expansion.
• Employees may benefit from the company's growth and expansion.
• Patients may benefit from the development of new therapies for rare neurological disorders.
• Customers may benefit from the continued availability of WAKIX and potential new products.
• Suppliers may benefit from the company's increased production and development activities.
• Creditors may benefit from the company's strong financial position.

Next Steps

• Submit a supplemental NDA (sNDA) for idiopathic hypersomnia (IH) in the fourth quarter of 2024.
• Initiate a pivotal bioequivalence study and dosing optimization study for Pitolisant GR in the first quarter of 2025.
• Initiate Phase 3 registrational studies for Pitolisant HD in the second half of 2025.
• Anticipate topline data from the ZYN002 Phase 3 study in mid-2025.
• Initiate a Phase 3 registrational study for ZYN002 in 22q deletion syndrome in 2025.
• File an IND for BP1.15205 in mid-2025 and begin first-in-human studies in the second half of 2025.
• Initiate a Phase 3 registrational clinical trial in patients with LGS in the fourth quarter of 2024.
• Initiate a juvenile toxicology study for HBS-102 in the fourth quarter of 2024.

Key Dates

Keywords

WAKIX, pitolisant, narcolepsy, idiopathic hypersomnia, Prader-Willi Syndrome, myotonic dystrophy, ZYN002, Fragile X Syndrome, EPX100, Dravet Syndrome, Lennox-Gastaut Syndrome, clinical trials, pharmaceutical, biotechnology, revenue, research and development, acquisition